Vaccinex (VCNX) 10-Q2023 Q2 Quarterly report

Filed: 14 Aug 23, 8:01am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: adenocarcinoma, AgreementSM, alternative, American, analyzed, avelumab, Bayesian, Biopsy, blockade, BOIN, carcinoma, cell, Center, central, Certificate, characterized, clarification, CLASSICAL, cold, committee, contrast, correlate, CPS, demonstrating, density, double, ductal, effector, enabling, exact, exemption, fail, formation, free, Gateway, hot, ICI, immunosuppression, infiltration, Interval, KEYNOTE, line, lung, lymphodepletion, lymphoid, MBC, MDSC, median, modulate, Moffitt, monotherapy, objective, observation, Optimal, organized, ORR, PDAC, PFS, population, proceed, progression, proposal, proposed, protocol, proxy, pulsed, ratio, rationale, reliance, rendering, responded, Restated, score, showed, similarly, Simon, Society, subgroup, submission, submit, submitted, suggest, suggesting, support, supported, suppression, survival, team, tertiary, therapy, TLS, TME, tolerated, trastuzumab, unexpected, University, Wilmot

Removed: consolidated, order, Rent

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

VCNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Vaccinex, Inc., (the "Company") on Form 10-Q for the three months ended June 30, 2023 (the "Report"), I, Maurice Zauderer, Ph.D., President and Chief Executive Officer of the Company and Scott E. Royer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: August 14, 2023	By:	/s/ Maurice Zauderer
		Maurice Zauderer, Ph.D.
		President and Chief Executive Officer



Dated: August 14, 2023	By:	/s/ Scott E. Royer
		Scott E. Royer
		Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.